• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Discovery of a Copy-neutral Loss of Heterozygosity Pattern in Perihilar Cholangiocarcinoma With Potential Prognostic Value.

作者信息

Techa-Ay Sutheemon, Watcharadetwittaya Sasithorn, Deenonpoe Raksawan, Intuyod Kitti, Techasen Anchalee, Klanrit Poramate, Loilome Watcharin, Sa-Ngiamwibool Prakasit, Thanee Malinee

机构信息

Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen, Thailand.

Department of Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.

出版信息

Anticancer Res. 2025 Sep;45(9):3737-3748. doi: 10.21873/anticanres.17734.

DOI:10.21873/anticanres.17734
PMID:40876993
Abstract

BACKGROUND/AIM: Perihilar cholangiocarcinoma (pCCA) is an aggressive bile duct cancer with a poor prognosis (10-40% 5-year survival after resection), that is mostly found in Thailand and has limited prognostic models. Copy neutral loss of heterozygosity (cnLOH) in various cancers affects their progression leading to poorer overall survival. This study aimed to explore cnLOH patterns in individual pCCA patients in order to develop a predictive model for prognostic biomarkers.

MATERIALS AND METHODS

DNA was extracted from 14 frozen tissues and chromosome microarray (CMA) was performed to analyze cnLOH.

RESULTS

Analysis of cnLOH revealed a median of 14 events per sample. The most frequent cnLOH was observed on chromosome 1q, followed by high occurrences on chromosomes 2, 3p, 5q, 6q, 7q, 11q, and 12q. Importantly, we identified several specific cnLOH regions (2p23.2, 2p23.3, and 6p11.1) where alterations were significantly associated with decreased overall survival (<0.05).

CONCLUSION

These results provide evidence that cnLOH events may contribute to disease progression and influence overall survival in patients with pCCA, indicating a potential role in the underlying molecular mechanisms of this malignancy.

摘要

相似文献

1
Discovery of a Copy-neutral Loss of Heterozygosity Pattern in Perihilar Cholangiocarcinoma With Potential Prognostic Value.
Anticancer Res. 2025 Sep;45(9):3737-3748. doi: 10.21873/anticanres.17734.
2
The clinicopathological factors associated with prognosis of patients with resectable perihilar cholangiocarcinoma: A systematic review and meta-analysis.可切除性肝门部胆管癌患者预后相关的临床病理因素:一项系统评价和荟萃分析
Medicine (Baltimore). 2018 Aug;97(34):e11999. doi: 10.1097/MD.0000000000011999.
3
Development of the Perihilar Cholangiocarcinoma Risk Estimation of Tumor Recurrence After Transplant (PRETREAT) Score.肝门周围胆管癌移植后肿瘤复发风险评估(PRETREAT)评分系统的开发。
Ann Surg. 2025 Sep 1;282(3):503-514. doi: 10.1097/SLA.0000000000006815. Epub 2025 Jun 23.
4
and Other Candidate Genes as Potential Biomarkers of Therapy Resistance in B-ALL: Insights from Chromosomal Microarray Analysis and Machine Learning.以及其他候选基因作为B-ALL治疗耐药性的潜在生物标志物:来自染色体微阵列分析和机器学习的见解
Int J Mol Sci. 2025 Aug 1;26(15):7437. doi: 10.3390/ijms26157437.
5
Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.可切除胆管癌的术后辅助化疗。
Cochrane Database Syst Rev. 2021 Sep 13;9(9):CD012814. doi: 10.1002/14651858.CD012814.pub2.
6
Methylation aberrations and genomic instability synergistically drive the evolution of intrahepatic cholangiocarcinoma.甲基化异常与基因组不稳定性协同驱动肝内胆管癌的进展。
Epigenomics. 2025 Jul;17(10):661-674. doi: 10.1080/17501911.2025.2518919. Epub 2025 Jun 17.
7
Are Current Survival Prediction Tools Useful When Treating Subsequent Skeletal-related Events From Bone Metastases?当前的生存预测工具在治疗骨转移后的骨骼相关事件时有用吗?
Clin Orthop Relat Res. 2024 Sep 1;482(9):1710-1721. doi: 10.1097/CORR.0000000000003030. Epub 2024 Mar 22.
8
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
9
Lymph node dissection in resectable perihilar cholangiocarcinoma: a systematic review.可切除性肝门周围胆管癌的淋巴结清扫:一项系统评价
Am J Surg. 2015 Oct;210(4):694-701. doi: 10.1016/j.amjsurg.2015.05.015. Epub 2015 Jun 29.
10
STRONG II trial: stereotactic body radiation therapy following chemotherapy for unresectable perihilar cholangiocarcinoma - a single-arm multicentre phase II study.STRONG II试验:不可切除的肝门部胆管癌化疗后立体定向体部放射治疗——一项单臂多中心II期研究。
BMJ Open. 2025 Jul 16;15(7):e097545. doi: 10.1136/bmjopen-2024-097545.